share_log

MIRA Pharmaceuticals | 8-K: Current report

MIRA Pharmaceuticals | 8-K: Current report

MIRA Pharmaceuticals | 8-K:重大事件
美股SEC公告 ·  2024/10/21 11:04

牛牛AI助理已提取核心訊息

MIRA Pharmaceuticals announced that its oral ketamine analog, Ketamir-2, has demonstrated superior efficacy compared to FDA-approved treatments Gabapentin (Neurontin) and Pregabalin (Lyrica) in recent preclinical models of neuropathic pain. The company is currently conducting additional studies focusing on chemotherapy-induced and diabetic neuropathy.The development program includes plans for PTSD trials, with the company exploring government funding opportunities for this initiative. MIRA remains on schedule to submit an Investigational New Drug (IND) application by end-2024, with Phase I clinical trials slated for Q1 2025 and Phase II trials projected to commence by late 2025.
MIRA Pharmaceuticals announced that its oral ketamine analog, Ketamir-2, has demonstrated superior efficacy compared to FDA-approved treatments Gabapentin (Neurontin) and Pregabalin (Lyrica) in recent preclinical models of neuropathic pain. The company is currently conducting additional studies focusing on chemotherapy-induced and diabetic neuropathy.The development program includes plans for PTSD trials, with the company exploring government funding opportunities for this initiative. MIRA remains on schedule to submit an Investigational New Drug (IND) application by end-2024, with Phase I clinical trials slated for Q1 2025 and Phase II trials projected to commence by late 2025.
MIRA製藥公司宣佈,其口服氯胺酮類似物Ketamir-2在最近的神經病理疼痛的臨牀前模型中顯示出優於FDA批准的治療藥物加巴噴丁(Neurontin)和普瑞巴林(Lyrica)的卓越療效。該公司目前正在進行其他研究,重點關注化療引起的神經病和糖尿病神經病。\n開發計劃包括針對創傷後壓力症候群(PTSD)試驗的計劃,該公司正在探討政府資助機會以推動這一倡議。MIRA仍按計劃在2024年底前提交新藥研究申請(IND),並計劃在2025年第一季度進行I期臨牀試驗,II期試驗預計將在2025年末開始。
MIRA製藥公司宣佈,其口服氯胺酮類似物Ketamir-2在最近的神經病理疼痛的臨牀前模型中顯示出優於FDA批准的治療藥物加巴噴丁(Neurontin)和普瑞巴林(Lyrica)的卓越療效。該公司目前正在進行其他研究,重點關注化療引起的神經病和糖尿病神經病。\n開發計劃包括針對創傷後壓力症候群(PTSD)試驗的計劃,該公司正在探討政府資助機會以推動這一倡議。MIRA仍按計劃在2024年底前提交新藥研究申請(IND),並計劃在2025年第一季度進行I期臨牀試驗,II期試驗預計將在2025年末開始。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 384

熱點推薦

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。